Atrium Therapeutics
(NASDAQ) RNA
Atrium Therapeutics Financials at a Glance
Market Cap
$233.49M
Revenue (TTM)
$25.04
Net Income (TTM)
-$64.73
EPS (TTM)
$0.00
P/E Ratio
0.00
Dividend
$0.00
Beta (Volatility)
0.30 (Low)
Dividend
$0.00
Beta (Volatility)
0.30 (Low)
Price
$13.65
Volume
196,855.893
Open
$13.40
Price
$13.65
Volume
196,855.893
Open
$13.40
Previous Close
$13.65
Daily Range
$13.20 - $13.72
52-Week Range
$11.40 - $16.77
Estimated Earnings Date
Aug 13, 2026
Dividend
$0.00
Beta (Volatility)
0.30 (Low)
Price
$13.65
Volume
196,855.893
Open
$13.40
Previous Close
$13.65
Daily Range
$13.20 - $13.72
52-Week Range
$11.40 - $16.77
Estimated Earnings Date
Aug 13, 2026
RNA News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Atrium Therapeutics
Industry
Biotechnology
Sector
Health CareCEO
Kathleen Gallagher
Website
www.atriumtherapeutics.comHeadquarters
San Diego, CA 92121, US
RNA Financials
Key Financial Metrics (TTM)
Gross Margin
99.26%
Operating Margin
-318.70%
Net Income Margin
-315.71%
Return on Equity
-29.67%
Return on Capital
-36.41%
Return on Assets
-22.13%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$233.49M
Shares Outstanding
17.11M
Volume
196.86K
Avg. Volume
297.61K
Financials (TTM)
Gross Profit
$20.34M
Operating Income
-$65.32M
EBITDA
-$64.40M
Operating Cash Flow
-$50.40M
Capital Expenditure
-$2.98M
Free Cash Flow
-$53.37M
Cash & ST Invst.
$267.85M
Total Debt
$2.68M
Atrium Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$19.64M
N/A
Gross Profit
$19.48M
N/A
Gross Margin
99.23%
N/A
Market Cap
$233.49M
N/A
Market Cap/Employee
$456.93K
N/A
Employees
511
N/A
Net Income
-$16.63M
N/A
EBITDA
-$16.48M
N/A
Quarterly Fundamentals
Total Cash
$267.85M
N/A
Total Debt
$2.68M
N/A
Accounts Receivable
$15.00M
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$2.68M
N/A
Return on Assets
-22.13%
N/A
Return on Invested Capital
-24.15%
N/A
Free Cash Flow
-$33.24M
N/A
Operating Cash Flow
-$31.14M
N/A